123 related articles for article (PubMed ID: 38553362)
61. Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas.
Guram K; Smith M; Ginader T; Bodeker K; Pelland D; Pennington E; Buatti JM
Pract Radiat Oncol; 2019 Jan; 9(1):16-23. PubMed ID: 30195927
[TBL] [Abstract][Full Text] [Related]
62. Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.
Eichkorn T; Lischalk JW; Hörner-Rieber J; Deng M; Meixner E; Krämer A; Hoegen P; Sandrini E; Regnery S; Held T; Harrabi S; Jungk C; Herfarth K; Debus J; König L
J Neurooncol; 2023 May; 162(3):489-501. PubMed ID: 36598613
[TBL] [Abstract][Full Text] [Related]
63. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
[TBL] [Abstract][Full Text] [Related]
64. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
65. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
66. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
[TBL] [Abstract][Full Text] [Related]
67. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
68. Volumetric response evaluation after intensity modulated radiotherapy in patients with supratentorial gliomas.
Cho KH; Choi JH; Kim JY; Lee SH; Yoo H; Shin KH; Kim TH; Moon SH; Lee SH; Park HC
Technol Cancer Res Treat; 2012 Feb; 11(1):41-8. PubMed ID: 22181330
[TBL] [Abstract][Full Text] [Related]
69. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
70. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
Doig D; Kachramanoglou C; Dumba M; Tona F; Gontsarova A; Limbäck C; Jan W
Clin Radiol; 2021 Oct; 76(10):785.e9-785.e16. PubMed ID: 34289936
[TBL] [Abstract][Full Text] [Related]
71. T2 mapping of molecular subtypes of WHO grade II/III gliomas.
Kern M; Auer TA; Picht T; Misch M; Wiener E
BMC Neurol; 2020 Jan; 20(1):8. PubMed ID: 31914945
[TBL] [Abstract][Full Text] [Related]
72. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G
World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029
[TBL] [Abstract][Full Text] [Related]
73. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
74. Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.
Galldiks N; Unterrainer M; Judov N; Stoffels G; Rapp M; Lohmann P; Vettermann F; Dunkl V; Suchorska B; Tonn JC; Kreth FW; Fink GR; Bartenstein P; Langen KJ; Albert NL
Neuro Oncol; 2019 Oct; 21(10):1331-1338. PubMed ID: 31077276
[TBL] [Abstract][Full Text] [Related]
75. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
76. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
77. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
[TBL] [Abstract][Full Text] [Related]
78. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.
Morshed RA; Han SJ; Hervey-Jumper SL; Pekmezci M; Troncon I; Chang SM; Butowski NA; Berger MS
J Neurooncol; 2019 Jan; 141(2):383-391. PubMed ID: 30498891
[TBL] [Abstract][Full Text] [Related]
79. Biological tumour volumes of gliomas in early and standard 20-40 min
Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
[TBL] [Abstract][Full Text] [Related]
80. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]